NONCLINICAL TOXICOLOGY SECTION.

13 NONCLINICAL TOXICOLOGY. 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. Long-term animal studies to determine the carcinogenic potential of Ecoza topical foam have not been performed.Oral administration of econazole nitrate in rats has been reported to produce prolonged gestation.

NURSING MOTHERS SECTION.

8.3 Nursing Mothers. It is not known whether econazole nitrate is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when econazole nitrate is administered to nursing woman. Following oral administration of econazole nitrate to lactating rats, econazole and/or metabolites were excreted in milk and were found in nursing pups.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.

PRINCIPAL DISPLAY PANEL 70 Canister Label. NDC 23710-100-70ecoza(TM) (econazole nitrate) topical foam, 1% For Topical Use OnlyNot for ophthalmic, oral or intravaginal use.Keep Out of Reach of ChildrenRx Only Net Wt 70g Exeltis Rethinking healthcare PRINCIPAL DISPLAY PANEL 70 Canister Label.

PEDIATRIC USE SECTION.

8.4 Pediatric Use. Of the 173 subjects treated with Ecoza topical foam, 1% in the clinical trials, subjects were 12 to 17 years old. In pediatric maximal use trial, Ecoza topical foam, 1% was applied once daily to eighteen subjects aged 12 to 17 years with interdigital tinea pedis for 28 days see Clinical Pharmacology (12.3) ]. The safety findings for subjects 12 to 17 years were similar to those in adult population.

PHARMACODYNAMICS SECTION.

12.2 Pharmacodynamics. The pharmacodynamics of Ecoza topical foam, 1% have not been established.

INSTRUCTIONS FOR USE SECTION.

Instructions for Use ECOZA (R) (ee-ko-zah) (econazole nitrate) topical foam, 1% Important information: Ecoza topical foam is for use on skin only.Do not use Ecoza topical foam in your eyes or vagina.Parts of Ecoza topical foam Canister. (See Figure A) Figure AHow to apply Ecoza topical foam:Step 1:Before you apply Ecoza topical foam, shake the Ecoza topical foam canister for about seconds.Step 2:Remove the cap and turn the Ecoza topical foam canister upside down over the palm of your hand.Step 3:Press down firmly on the actuator until there is small amount of foam about the size of golf ball in the palm of your hand. (See Figures and C) Figure BFigure CStep 4:Use your finger-tips to scoop up small amounts of Ecoza topical foam and apply to the affected skin areas on your feet. Gently rub the foam into the skin. (See Figure D) Figure DStep 5:You should apply Ecoza topical foam to your toes, to the spaces between your toes, and to the surrounding areas time day for weeks or as prescribed by your doctor.Step 6:Replace the cap. Wash your hands after applying Ecoza topical foam.How should store Ecoza topical foamStore Ecoza topical foam at room temperature, between 68F to 77F (20C to 25C).Do not refrigerate or freeze Ecoza topical foam.Do not store Ecoza topical foam in direct sunlight.Ecoza topical foam is flammable. Keep the Ecoza topical foam canister away from heat and temperatures above 120F (49C), even if the canister is empty.Do not puncture or burn the Ecoza topical foam canister.Keep Ecoza topical foam and all medicines out of the reach of children.This Instructions for Use has been approved by the U.S. Food and Drug Administration.Manufactured for Exeltis USA Dermatology, LLC Florham Park, NJ 07932Issued: 07/2016. Store Ecoza topical foam at room temperature, between 68F to 77F (20C to 25C).. Do not refrigerate or freeze Ecoza topical foam.. Do not store Ecoza topical foam in direct sunlight.. Ecoza topical foam is flammable. Keep the Ecoza topical foam canister away from heat and temperatures above 120F (49C), even if the canister is empty.. Do not puncture or burn the Ecoza topical foam canister.. Figure A. Figure B. Figure C. Figure D.

MECHANISM OF ACTION SECTION.

12.1 Mechanism of Action. Ecoza topical foam is an azole antifungal see Clinical Pharmacology (12.4).

MICROBIOLOGY SECTION.

12.4 Microbiology. Mechanism of ActionEconazole nitrate, an azole antifungal agent, inhibits fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylase enzyme. This enzyme functions to convert lanosterol to ergosterol. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell wall and may be responsible for the fungistatic activity of econazole. Mammalian cell demethylation is less sensitive to econazole inhibition.. Activity in vitro and in clinical infections Econazole nitrate has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections see Indications and Usage (1) ]. Trichophyton rubrumEpidermophyton floccosumTrichophyton mentagrophytes.

ADVERSE REACTIONS SECTION.

6 ADVERSE REACTIONS. During clinical trials with Ecoza topical foam, the most common adverse reactions were application site reactions which occurred in less than 1% of subjects in both the Ecoza and vehicle arms. 6.1) To report SUSPECTED ADVERSE REACTIONS, contact Quinnova Pharmaceuticals at 1-877-660-6263 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.. 6.1 Clinical Trials Experience. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.In two double-blind, vehicle-controlled clinical trials, 495 subjects were exposed to Ecoza topical foam or vehicle (246 subjects were exposed to Ecoza topical foam, 1% and 249 were exposed to vehicle). Subjects with interdigital tinea pedis applied foam or vehicle once daily for approximately 28 days. During clinical trials with Ecoza topical foam, the most common adverse reactions were application site reactions which occurred in less than 1% of subjects in both the Ecoza and vehicle arms.

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION.

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. Long-term animal studies to determine the carcinogenic potential of Ecoza topical foam have not been performed.Oral administration of econazole nitrate in rats has been reported to produce prolonged gestation.

CLINICAL PHARMACOLOGY SECTION.

12 CLINICAL PHARMACOLOGY. 12.1 Mechanism of Action. Ecoza topical foam is an azole antifungal see Clinical Pharmacology (12.4) . 12.2 Pharmacodynamics. The pharmacodynamics of Ecoza topical foam, 1% have not been established . 12.3 Pharmacokinetics. The systemic absorption of Ecoza topical foam, 1% following topical application was studied in one clinical trial in adults and one clinical study in pediatric subjects.In the adult trial, 19 subjects (male and female) with tinea pedis applied Ecoza topical foam, 1% once daily for 29 days. Subjects applied mean daily amount of 2.4 of Ecoza topical foam, 1% to soles, toes, interdigital spaces and tops of both feet up to the ankles. Blood samples were obtained on Day 29 at pre-dose and 1, 2, 4, 6, 8, and 12 hours after application. Results (mean +- SD) showed the time to reach peak plasma concentrations (T max) was 6.8 +- 5.1 with maximum concentration (C max) of 417 +- 218 pg/ml. The area under the concentration time curve for the first 12 hours post application on Day 29 (AUC (0-12)) was 3440 +- 1920 pg-h/ml. In the pediatric trial, 18 subjects (male and female ages 12 17) with interdigital tinea pedis and positive fungal cultures were treated with Ecoza topical foam, 1% once daily for weeks. Subjects applied mean daily amount of 3.2 of Ecoza topical foam, 1% to soles, toes, interdigital spaces and tops of both feet up to the ankles. Blood samples were obtained on Day 28 at pre-dose and h and 11 post-dose. The mean +- SD econazole plasma concentration was 397 +- 289, 534 +- 745 and 575 +- 638 pg/mL at pre-dose and h and 11 post-dose, respectively.. 12.4 Microbiology. Mechanism of ActionEconazole nitrate, an azole antifungal agent, inhibits fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylase enzyme. This enzyme functions to convert lanosterol to ergosterol. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell wall and may be responsible for the fungistatic activity of econazole. Mammalian cell demethylation is less sensitive to econazole inhibition.. Activity in vitro and in clinical infections Econazole nitrate has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections see Indications and Usage (1) ]. Trichophyton rubrumEpidermophyton floccosumTrichophyton mentagrophytes.

CLINICAL STUDIES SECTION.

14 CLINICAL STUDIES. In two multi-center, randomized, double-blind, vehicle-controlled clinical trials total of 505 subjects with interdigital tinea pedis were randomized 1:1 to Ecoza topical foam or vehicle; subjects applied the assigned medication once daily for weeks. The severity of erythema, scaling, fissuring, maceration, vesiculation, and pruritus were graded using 4-point scale (none, mild, moderate, severe). Subjects had KOH examination and fungal cultures taken to confirm eligibility. total of 339 subjects with positive fungal cultures were evaluated for efficacy. Efficacy was evaluated on Day 43, weeks post-treatment with treatment success being defined as complete cure (negative KOH and fungal culture and no evidence of clinical disease). The study population ranged in age from 12 to 71 years with subjects less than 18 years of age at baseline. The subjects were 71% male and 51% Caucasian. Table presents the efficacy results for each trial.Table 1: Efficacy Results at Two Weeks Post-treatment (Day 43) Complete Cure, Effective Treatment and Mycological CureTrial 1Trial 2Ecoza topical foam, 1% = 82 n(%) Foam Vehicle = 83 n(%) Ecoza topical foam, 1% = 91 n(%) Foam Vehicle = 83 n(%) Complete cureMycological cure and an absence of clinical signs and symptoms (erythema, scaling, fissuring, maceration, vesiculation, or pruritus).19 (23.2%)2 (2.4%)23 (25.3%)4 (4.8%)Effective treatmentMycological cure and no or mild erythema and/or scaling with all other signs and symptoms absent.40 (48.8%)9 (10.8%)44 (48.4%)9 (10.8%)Mycological cureNegative KOH and fungal culture.56 (68.3%)13 (15.7%)61 (67.0%)15 (18.1%).

CLINICAL TRIALS EXPERIENCE SECTION.

6.1 Clinical Trials Experience. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.In two double-blind, vehicle-controlled clinical trials, 495 subjects were exposed to Ecoza topical foam or vehicle (246 subjects were exposed to Ecoza topical foam, 1% and 249 were exposed to vehicle). Subjects with interdigital tinea pedis applied foam or vehicle once daily for approximately 28 days. During clinical trials with Ecoza topical foam, the most common adverse reactions were application site reactions which occurred in less than 1% of subjects in both the Ecoza and vehicle arms.

CONTRAINDICATIONS SECTION.

4 CONTRAINDICATIONS. None.. None. 4).

DESCRIPTION SECTION.

11 DESCRIPTION. Ecoza (econazole nitrate) topical foam, 1% contains the azole antifungal agent, econazole nitrate in an oil-in-water emulsion base consisting of the following inactive ingredients: dimethicone, glycerin, polysorbate 20, povidone, propylene glycol, stearic acid, trolamine, purified water and butane as propellant. Each gram of Ecoza topical foam, 1% contains 10 mg of econazole nitrate, USP, in white to off-white foam. Ecoza topical foam, 1% is alcohol (ethanol)-free and for topical use only.Chemically, econazole nitrate is 1-[2-(4-chloro-phenyl)methoxy-2-(2,4-dichlorophenyl) ethyl]-1H-imidazole mononitrate. Econazole nitrate has the molecular formula 18H 15Cl 3N 2O. HNO and molecular weight of 444.70. Its molecular structure is as follows: Chemical Structure.

DOSAGE & ADMINISTRATION SECTION.

2 DOSAGE AND ADMINISTRATION. Ecoza topical foam, 1% is for topical use only. Ecoza topical foam, 1% is not for oral, ophthalmic, or intravaginal use.Ecoza topical foam, 1% should be applied to cover affected areas once daily for weeks.. For topical use only; not for oral, ophthalmic, or intravaginal use. 2) Apply once daily for weeks. 2) For topical use only; not for oral, ophthalmic, or intravaginal use. 2) Apply once daily for weeks. 2).

DOSAGE FORMS & STRENGTHS SECTION.

3 DOSAGE FORMS AND STRENGTHS. Foam, 1%. Each gram of Ecoza topical foam, 1%, contains 10 mg of econazole nitrate in white to off-white foam.. Foam, 1%. 3).

DRUG INTERACTIONS SECTION.

7 DRUG INTERACTIONS. 7.1 Warfarin. Concomitant administration of econazole and warfarin has resulted in enhancement of anticoagulant effect. Most cases reported product application with use under occlusion, genital application, or application to large body surface area which may increase the systemic absorption of econazole nitrate. Monitoring of International Normalized Ratio (INR) and/or prothrombin time may be indicated especially for patients who apply econazole to large body surface areas, in the genital area, or under occlusion.

GERIATRIC USE SECTION.

8.5 Geriatric Use. Of the 173 subjects treated with Ecoza topical foam, 1% in the adult clinical trials, subjects were 65 years or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects.

HOW SUPPLIED SECTION.

16 HOW SUPPLIED/ STORAGE AND HANDLING. Ecoza topical foam, 1% is white to off-white foam supplied in 10g (NDC 23710-100-10) and 70g (NDC 23710-100-75) aluminum pressurized canister.. Store at controlled room temperature 20C to 25C (68F to 77F) with excursions permitted between 15C and 30C (59F and 86F). Do not refrigerate or freeze.Ecoza topical foam is flammable. Avoid heat, flame, and smoking during and immediately following application.Contents under pressure. Do not puncture and/or incinerate the containers.Do not expose containers to heat and/or store at temperatures above 120F (49C) even when empty.Do not store in direct sunlight.

INDICATIONS & USAGE SECTION.

1 INDICATIONS AND USAGE. Ecoza (econazole nitrate) topical foam, 1%, is indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older. Ecoza is an azole antifungal indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older. 1).

INFORMATION FOR PATIENTS SECTION.

17 PATIENT COUNSELING INFORMATION. See FDA-approved patient labeling (Patient Information) The patient should be instructed as follows:Inform patients that Ecoza (econazole nitrate) topical foam, 1% is for topical use only. Ecoza (econazole nitrate) topical foam, 1% is not intended for oral, intravaginal, or ophthalmic use.Ecoza topical foam, 1% is flammable; avoid heat, flame, and smoking during and immediately following application.If reaction suggesting sensitivity or chemical irritation develops with the use of Ecoza topical foam, 1%, use of the medication should be discontinued.. Inform patients that Ecoza (econazole nitrate) topical foam, 1% is for topical use only. Ecoza (econazole nitrate) topical foam, 1% is not intended for oral, intravaginal, or ophthalmic use.. Ecoza topical foam, 1% is flammable; avoid heat, flame, and smoking during and immediately following application.. If reaction suggesting sensitivity or chemical irritation develops with the use of Ecoza topical foam, 1%, use of the medication should be discontinued.

PHARMACOKINETICS SECTION.

12.3 Pharmacokinetics. The systemic absorption of Ecoza topical foam, 1% following topical application was studied in one clinical trial in adults and one clinical study in pediatric subjects.In the adult trial, 19 subjects (male and female) with tinea pedis applied Ecoza topical foam, 1% once daily for 29 days. Subjects applied mean daily amount of 2.4 of Ecoza topical foam, 1% to soles, toes, interdigital spaces and tops of both feet up to the ankles. Blood samples were obtained on Day 29 at pre-dose and 1, 2, 4, 6, 8, and 12 hours after application. Results (mean +- SD) showed the time to reach peak plasma concentrations (T max) was 6.8 +- 5.1 with maximum concentration (C max) of 417 +- 218 pg/ml. The area under the concentration time curve for the first 12 hours post application on Day 29 (AUC (0-12)) was 3440 +- 1920 pg-h/ml. In the pediatric trial, 18 subjects (male and female ages 12 17) with interdigital tinea pedis and positive fungal cultures were treated with Ecoza topical foam, 1% once daily for weeks. Subjects applied mean daily amount of 3.2 of Ecoza topical foam, 1% to soles, toes, interdigital spaces and tops of both feet up to the ankles. Blood samples were obtained on Day 28 at pre-dose and h and 11 post-dose. The mean +- SD econazole plasma concentration was 397 +- 289, 534 +- 745 and 575 +- 638 pg/mL at pre-dose and h and 11 post-dose, respectively.

PREGNANCY SECTION.

8.1 Pregnancy. Pregnancy Category CThere are no adequate and well-controlled trials with Ecoza topical foam in pregnant women. Ecoza topical foam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Econazole nitrate has not been shown to be teratogenic when administered orally to mice, rabbits or rats. Fetotoxic or embryotoxic effects were observed in Segment oral studies with rats receiving 10 to 40 times the human dermal dose. Similar effects were observed in Segment II or Segment III studies with mice, rabbits and/or rats receiving oral doses 80 or 40 times the human dermal dose.

SPL PATIENT PACKAGE INSERT SECTION.

Patient Information ECOZA (R) (ee-ko-zah) (econazole nitrate) topical foam, 1% Important information: Ecoza topical foam is for use on skin only. Do not use Ecoza topical foam in your eyes or vagina. What is Ecoza topical foamEcoza topical foam is prescription medicine used on the skin (topical) to treat athletes foot that is between the toes (interdigital tinea pedis) in people 12 years of age and older.What should tell my doctor before using Ecoza topical foamBefore using Ecoza topical foam, tell your doctor about all of your medical conditions, including if you:are pregnant or plan to become pregnant. It is not known if Ecoza topical foam will harm your unborn baby.are breastfeeding or plan to breastfeed. It is not known if Ecoza topical foam passes into your breast milk.Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. How should use Ecoza topical foamSee the detailed Instructions for Use for information about how to use Ecoza topical foam. Use Ecoza topical foam exactly as your doctor tells you to use it.Apply Ecoza topical foam to the affected skin areas of your feet time day for weeks.If Ecoza topical foam gets in or near your eyes, rinse them well with water.Wash your hands after you apply Ecoza topical foam.What should avoid while using Ecoza topical foamEcoza topical foam is flammable. Avoid heat, flame and smoking while applying and right after you apply Ecoza topical foam to your skin.What are the possible side effects of Ecoza topical foamEcoza topical foam may cause skin reactions at the treatment site. Tell your doctor if you have any skin reactions on the areas of your skin treated with Ecoza topical foam.These are not all the possible side effects of Ecoza topical foam.Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.How should store Ecoza topical foamStore Ecoza topical foam at room temperature, between 68F to 77F (20C to 25C).Do not refrigerate or freeze Ecoza topical foam.Do not store Ecoza topical foam in direct sunlight.Ecoza topical foam is flammable. Keep the Ecoza topical foam canister away from heat and temperatures above 120F (49C), even if the canister is empty.Do not puncture or burn the Ecoza topical foam canister.Keep Ecoza topical foam and all medicines out of the reach of children.General information about the safe and effective use of Ecoza topical foamMedicines are sometimes prescribed for purposes other than those listed in Patient Information leaflet. You can ask your doctor or pharmacist for information about Ecoza topical foam that is written for health professionals. Do not use Ecoza topical foam for condition for which it was not prescribed. Do not give Ecoza topical foam to other people, even if they have the same symptoms that you have. It may harm them.What are the ingredients in Ecoza topical foamActive ingredient: econazole nitrate USP Inactive Ingredients: dimethicone, glycerin, polysorbate 20, povidone, propylene glycol, stearic acid, trolamine, purified water and butane as propellant. Manufactured for Exeltis USA Dermatology, LLC Florham Park, NJ 07932For more information call Exeltis USA, Inc. at 1-877-324-9349.This Patient Information has been approved by the U.S. Food and Drug Administration.Issued:07/20161007501-02. are pregnant or plan to become pregnant. It is not known if Ecoza topical foam will harm your unborn baby.. are breastfeeding or plan to breastfeed. It is not known if Ecoza topical foam passes into your breast milk.. Use Ecoza topical foam exactly as your doctor tells you to use it.. Apply Ecoza topical foam to the affected skin areas of your feet time day for weeks.. If Ecoza topical foam gets in or near your eyes, rinse them well with water.. Wash your hands after you apply Ecoza topical foam.. Ecoza topical foam is flammable. Avoid heat, flame and smoking while applying and right after you apply Ecoza topical foam to your skin.. Store Ecoza topical foam at room temperature, between 68F to 77F (20C to 25C).. Do not refrigerate or freeze Ecoza topical foam.. Do not store Ecoza topical foam in direct sunlight.. Ecoza topical foam is flammable. Keep the Ecoza topical foam canister away from heat and temperatures above 120F (49C), even if the canister is empty.. Do not puncture or burn the Ecoza topical foam canister.

SPL UNCLASSIFIED SECTION.

5.1 Flammability. Ecoza topical foam is flammable. Avoid heat, flame, and smoking during and immediately following application. Contents under pressure. Do not puncture and/or incinerate the containers. Do not expose containers to heat and/or store at temperatures above 120F (49C) even when empty. Do not store in direct sunlight.

STORAGE AND HANDLING SECTION.

Store at controlled room temperature 20C to 25C (68F to 77F) with excursions permitted between 15C and 30C (59F and 86F). Do not refrigerate or freeze.Ecoza topical foam is flammable. Avoid heat, flame, and smoking during and immediately following application.Contents under pressure. Do not puncture and/or incinerate the containers.Do not expose containers to heat and/or store at temperatures above 120F (49C) even when empty.Do not store in direct sunlight.

TERATOGENIC EFFECTS SECTION.

Pregnancy Category CThere are no adequate and well-controlled trials with Ecoza topical foam in pregnant women. Ecoza topical foam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Econazole nitrate has not been shown to be teratogenic when administered orally to mice, rabbits or rats. Fetotoxic or embryotoxic effects were observed in Segment oral studies with rats receiving 10 to 40 times the human dermal dose. Similar effects were observed in Segment II or Segment III studies with mice, rabbits and/or rats receiving oral doses 80 or 40 times the human dermal dose.

USE IN SPECIFIC POPULATIONS SECTION.

8 USE IN SPECIFIC POPULATIONS. 8.1 Pregnancy. Pregnancy Category CThere are no adequate and well-controlled trials with Ecoza topical foam in pregnant women. Ecoza topical foam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Econazole nitrate has not been shown to be teratogenic when administered orally to mice, rabbits or rats. Fetotoxic or embryotoxic effects were observed in Segment oral studies with rats receiving 10 to 40 times the human dermal dose. Similar effects were observed in Segment II or Segment III studies with mice, rabbits and/or rats receiving oral doses 80 or 40 times the human dermal dose.. 8.3 Nursing Mothers. It is not known whether econazole nitrate is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when econazole nitrate is administered to nursing woman. Following oral administration of econazole nitrate to lactating rats, econazole and/or metabolites were excreted in milk and were found in nursing pups.. 8.4 Pediatric Use. Of the 173 subjects treated with Ecoza topical foam, 1% in the clinical trials, subjects were 12 to 17 years old. In pediatric maximal use trial, Ecoza topical foam, 1% was applied once daily to eighteen subjects aged 12 to 17 years with interdigital tinea pedis for 28 days see Clinical Pharmacology (12.3) ]. The safety findings for subjects 12 to 17 years were similar to those in adult population. 8.5 Geriatric Use. Of the 173 subjects treated with Ecoza topical foam, 1% in the adult clinical trials, subjects were 65 years or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects.

WARNINGS AND PRECAUTIONS SECTION.

5 WARNINGS AND PRECAUTIONS. Contents are flammable. Instruct the patient to avoid heat, flame, and/or smoking during and immediately following application. 5.1) 5.1 Flammability. Ecoza topical foam is flammable. Avoid heat, flame, and smoking during and immediately following application. Contents under pressure. Do not puncture and/or incinerate the containers. Do not expose containers to heat and/or store at temperatures above 120F (49C) even when empty. Do not store in direct sunlight.